According to a study published in Nature Cancer, scientists at the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH), have created an artificial intelligence tool that uses individual tumor cells to forecast whether a patient will respond to cancer therapy medicines.
Conventional methods of medication-patient matching center on large-scale sequencing of tumor DNA and RNA. PERCEPTION, a novel artificial intelligence technique, leverages single-cell RNA sequencing to refine anticipated medication reactions through higher resolution data.
In two clinical trials, the novel strategy demonstrated promise for treating breast cancer and myeloma.
Researchers were able to determine the most effective treatment for a particular patient thanks to the study, which assigned a numerical value to the efficacy of clinical trial drug combinations and ranked them highest based on individual tumor cell responses to the therapies.
THE MAJOR TREND
In October, NIH declared that a tablet application could be used for autism early screening, based on research it had financed. The goal of the study is to provide patients and parents with the necessary support by accurately identifying patients at an early age.
The Cancer Screen Research Network was established by the NIH in February with the aim of detecting cancer early through the evaluation of cutting-edge technology in cancer screening. This year, the network intends to start a pilot study to evaluate the efficacy of multi-cancer detection in clinical trials.
A study published in Nature on April 11 by the NIH modified an AI software to forecast symptoms of postpartum PTSD. In order to determine whether patients are at risk for the illness, the tool looks at patient testimonials from women who have given birth.
Drug research in the life sciences is one area where artificial intelligence is heavily utilized.
AION Labs, an AI-enabled drug discovery business based in Israel, was established through a government tender. Global pharmaceutical and tech giants AstraZeneca, Merck, Pfizer, and Teva joined forces with venture finance firm Israel Biotech Fund, Amazon Web Services as a strategic partner, and German independent research institute Bio Med X to develop the organization.
